Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Lantheus (LNTH)

Lantheus Q4 revenue rises 4.0% to $406.8 million; 2026 revenue guided to $1.4-$1.45 billion

Mixed Impact 4 of 5 earnings Written later

Lantheus reported fourth-quarter 2025 revenue of $406.8 million, up 4.0%, and GAAP diluted EPS of $0.82 versus a loss of $(0.17) a year earlier. For full year 2025, revenue was $1.54 billion, up 0.5%, while adjusted diluted EPS fell to $6.08 from $6.76. The company also said it is pursuing value-maximizing alternatives for its radiotherapeutic assets and issued 2026 revenue guidance of $1.4 billion to $1.45 billion and adjusted diluted EPS guidance of $5.00 to $5.25.

Key points

  • Q4 2025 revenue $406.8 million, up 4.0%; Q4 adjusted operating income down 8.5% to $138.9 million
  • Full year 2025 GAAP diluted EPS $3.41 versus $4.36 in 2024; adjusted diluted EPS $6.08 versus $6.76
  • Company repurchased $100 million of common stock in Q4 2025 and completed the divestiture of the legacy SPECT business to SHINE Technologies effective January 1, 2026
  • FY 2026 guidance: revenue $1.4 billion to $1.45 billion; adjusted diluted EPS $5.00 to $5.25

The filing

CompanyLantheus (LNTH)
Form8-K, current report
Filed with the SECFeb 26, 2026, 7:38 AM ET
Accession number0001193125-26-073439

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.